NO20084663L - 1,3,4-oksadiazol-derivater som DGAT1 inhibitorer - Google Patents

1,3,4-oksadiazol-derivater som DGAT1 inhibitorer

Info

Publication number: NO20084663L
Authority: NO; Norway
Prior art keywords: oxadiazole derivatives; dgat1 inhibitors; dgat1; acetyl; inhibitors
Prior art date: 2006-05-30

Application number

NO20084663A

Other languages

English (en)

Norwegian (no)

Inventor

Craig Johnstone

Alleyn Plowright

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-05-30

Filing date

2008-11-05

Publication date

2008-12-12

2008-11-05 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2008-12-12 Publication of NO20084663L publication Critical patent/NO20084663L/no

Links

150000005072 1,3,4-oxadiazoles Chemical class 0.000 title 1
229940127193 DGAT1 inhibitor Drugs 0.000 title 1
ZSLZBFCDCINBPY-ZSJPKINUSA-N acetyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 ZSLZBFCDCINBPY-ZSJPKINUSA-N 0.000 abstract 4
102000002148 Diacylglycerol O-acyltransferase Human genes 0.000 abstract 2
108010001348 Diacylglycerol O-acyltransferase Proteins 0.000 abstract 2
-1 cyano, methyl Chemical group 0.000 abstract 2
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 abstract 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 1
229940100228 acetyl coenzyme a Drugs 0.000 abstract 1
229910052801 chlorine Inorganic materials 0.000 abstract 1
239000000460 chlorine Substances 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
239000003814 drug Substances 0.000 abstract 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
229910052731 fluorine Inorganic materials 0.000 abstract 1
239000011737 fluorine Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000000825 pharmaceutical preparation Substances 0.000 abstract 1
238000002360 preparation method Methods 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D271/113—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

NO20084663A 2006-05-30 2008-11-05 1,3,4-oksadiazol-derivater som DGAT1 inhibitorer NO20084663L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US80929706P	2006-05-30	2006-05-30
PCT/GB2007/001981 WO2007138304A1 (fr)	2006-05-30	2007-05-29	Dérivés du 1,3,4-oxadiazole en tant qu'inhibiteurs de dgat1

Publications (1)

Publication Number	Publication Date
NO20084663L true NO20084663L (no)	2008-12-12

Family

ID=38308729

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20084663A NO20084663L (no)	2006-05-30	2008-11-05	1,3,4-oksadiazol-derivater som DGAT1 inhibitorer

Country Status (14)

Country	Link
US (1)	US8003676B2 (fr)
EP (1)	EP2041099A1 (fr)
JP (1)	JP2009538891A (fr)
KR (1)	KR20090010092A (fr)
CN (1)	CN101460470B (fr)
AU (1)	AU2007266890B2 (fr)
BR (1)	BRPI0712796A2 (fr)
CA (1)	CA2651663A1 (fr)
IL (1)	IL195125A0 (fr)
MX (1)	MX2008015226A (fr)
NO (1)	NO20084663L (fr)
NZ (1)	NZ572585A (fr)
WO (1)	WO2007138304A1 (fr)
ZA (1)	ZA200809689B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2007007101A (es) *	2004-12-14	2007-08-21	Astrazeneca Ab	Derivados de oxadiazol como inhibidores de acil coa:diacilglicerol aciltransferasa.
AR058562A1 (es)	2005-12-22	2008-02-13	Astrazeneca Ab	Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1
WO2007126957A2 (fr)	2006-03-31	2007-11-08	Novartis Ag	Nouveaux composés
BRPI0712802A2 (pt)	2006-05-30	2012-10-23	Astrazeneca Ab	composto, métodos para produzir uma inibição da atividade de dgat1, e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para preparar um composto
CA2651663A1 (fr)	2006-05-30	2007-12-06	Astrazeneca Ab	Composes chimiques
JP2009539818A (ja) *	2006-06-08	2009-11-19	アストラゼネカアクチボラグ	ベンゾイミダゾールおよび糖尿病の処置のためのその使用
JP2010536839A (ja) *	2007-08-17	2010-12-02	アストラゼネカアクチボラグ	化合物９７９
AR066169A1 (es)	2007-09-28	2009-07-29	Novartis Ag	Derivados de benzo-imidazoles, utiles para trastornos asociados con la actividad de dgat
CN101932562B (zh)	2007-12-20	2013-06-12	阿斯利康(瑞典)有限公司	作为dgat1抑制剂190的氨基甲酰基化合物
WO2010023609A1 (fr)	2008-08-25	2010-03-04	Piramal Life Sciences Limited	Dérivés d’oxazole, d’oxadiazole et de thiazole comme inhibiteurs de la diacylglycérol acyltransférase
MX2011006672A (es) *	2008-12-19	2011-07-20	Astrazeneca Ab	Derivados de 1,3,4-oxadiazol y sus usos para tratar diabetes.
DK3366686T3 (da)	2009-03-20	2020-11-23	Metabasis Therapeutics Inc	Inhibitorer af diacylglycerol-o-acyltransferase 1 (dgat-1) og anvendelser deraf
MX2011011178A (es)	2009-04-21	2011-12-06	Astellas Pharma Inc	Compuesto de diaciletilendiamina.
WO2010146395A1 (fr) *	2009-06-19	2010-12-23	Astrazeneca Ab	Carboxamides de pyrazine utiles comme inhibiteurs de la dgat1
FR2963005B1 (fr) *	2010-07-23	2012-08-17	Sanofi Aventis	Derives d'oxadiazoles et de pyridazines, leur preparation et leur application en therapeutique
EP2683704B1 (fr)	2011-03-08	2014-12-17	Sanofi	Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
US8710050B2 (en)	2011-03-08	2014-04-29	Sanofi	Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en)	2011-03-08	2014-10-28	Sanofi	Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8828994B2 (en)	2011-03-08	2014-09-09	Sanofi	Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2766349B1 (fr)	2011-03-08	2016-06-01	Sanofi	Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2013056679A1 (fr) *	2011-10-21	2013-04-25	Beijing Hanmi Pharmaceutical Co., Ltd	Nouveaux dérivés amino-hétéroaryle
CN107667025B (zh)	2015-06-22	2020-10-16	大陆汽车有限责任公司	具有可控屏蔽显示器的透明显示器
CN118243845B (zh) *	2024-03-13	2026-03-06	浙江大学	一种评估脂质吸收的再酯化测定方法及应用

Family Cites Families (80)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3245989A (en) *	1962-12-15	1966-04-12	Acraf	3-aminophenyl-5-aminoloweralkyl-1, 2, 4-oxadiazoles
US4983731A (en) *	1989-03-17	1991-01-08	Nebraska Department Of Economic Development	Separation and purification of sugar esters
US5491172A (en) *	1993-05-14	1996-02-13	Warner-Lambert Company	N-acyl sulfamic acid esters (or thioesters), N-acyl sulfonamides, and N-sulfonyl carbamic acid esters (or thioesters) as hypercholesterolemic agents
IL109431A (en)	1993-05-14	2001-01-11	Warner Lambert Co	Pharmaceutical compositions containing n-acyl sulfamic acid esters (or thioesters), n-acyl sulfonamides, and n-sulfonyl carbamic acid esters (or thioesters), for regulating plasma cholesterol concentration, and certain such novel compounds
US20030167483A1 (en) *	1998-06-24	2003-09-04	Farese Robert V.	Diacylglycerol O-acyltransferase
WO2000058491A1 (fr)	1999-03-25	2000-10-05	The Kitasato Institute	Nouvelles substances kf-1040t4a, kf-1040t4b, kf-1040t5a et kf-1040t5b et leur procede de production
TW518218B (en)	1999-05-27	2003-01-21	Merck Patent Gmbh	Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
GB0021670D0 (en)	2000-09-04	2000-10-18	Astrazeneca Ab	Chemical compounds
CA2369967A1 (fr)	2001-02-12	2002-08-12	Joseph Anthony Cornicelli	Methodes de traitement de maladies et de troubles relies au facteur nucleaire-kappa b
JP2002284741A (ja)	2001-03-23	2002-10-03	Kitasato Inst:The	ローズリピン誘導体
DE10223273A1 (de)	2002-05-24	2003-12-04	Aventis Pharma Gmbh	Diarylcycloalkylderivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP4436129B2 (ja) *	2001-08-31	2010-03-24	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	ジアリールシクロアルキル誘導体、その製造法及びｐｐａｒ−活性剤としてのその使用
FR2840301B1 (fr)	2002-05-29	2007-03-23	Sanofi Synthelabo	Derives de phenyl-cyclohexyl-propanolamine, leur preparation et leur applicaton en therapeutique
MXPA05000279A (es) *	2002-07-09	2005-03-31	Squibb Bristol Myers Co	Derivados heterociclicos sustituidos utiles como agentes antidiabeticos y antiobesidad y metodo.
EP1541563A4 (fr)	2002-07-10	2007-11-07	Ono Pharmaceutical Co	Antagoniste du ccr4 et utilisation medicinale correspondante
DE50312261D1 (de) *	2002-07-12	2010-02-04	Sanofi Aventis Deutschland	Heterozyklisch substituierte benzoylharnstoffe, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JP4164645B2 (ja)	2002-08-09	2008-10-15	株式会社大塚製薬工場	Ｄｇａｔ阻害剤
AU2003265659A1 (en)	2002-08-23	2004-03-11	University Of Connecticut	Novel biphenyl and biphenyl-like cannabinoids
US7189712B2 (en)	2002-10-10	2007-03-13	Smithkline Beecham Corporation	1,3-Oxazole compounds for the treatment of cancer
AU2003293006A1 (en)	2002-11-22	2004-06-18	Japan Tobacco Inc.	Fused bicyclic nitrogen-containing heterocycles
SG2012000667A (en)	2003-01-08	2015-03-30	Univ Washington	Antibacterial agents
EP1611120A4 (fr)	2003-04-07	2008-04-23	Cortical Pty Ltd	Nouvelles m thodes de traitement des maladies inflammatoires
AR044152A1 (es)	2003-05-09	2005-08-24	Bayer Corp	Derivados de alquilarilo, metodo de preparacion y uso para el tratamiento de la obesidad
EP1628666B1 (fr)	2003-05-14	2015-09-23	NeuroGenetic Pharmaceuticals, Inc.	Composes et leurs utilisations pour la modulation de l'amyloide-beta
EP1653969A4 (fr) *	2003-08-07	2006-12-20	Japan Tobacco Inc	Derives de pyrrolo 1,2-b pyridazine
EP1661889A4 (fr)	2003-09-05	2009-08-05	Ono Pharmaceutical Co	Antagoniste du recepteur de la chimiokine et son utilisation a des fins medicales
US20050143464A1 (en)	2003-09-22	2005-06-30	Use-Techno Corporation	Insulin secretion potentiator
BRPI0415500A (pt)	2003-10-17	2007-04-10	Incyte Corp	hidroxamatos cìclicos substituìdos como inibidores de metaloproteinases de matriz
GB0325192D0 (en)	2003-10-29	2003-12-03	Astrazeneca Ab	Method of use
US20050101660A1 (en)	2003-11-11	2005-05-12	The Skinny Drink Company	Composition for prevention and treatment of obesity, cardiovascular and coronary artery disease
US7507832B2 (en) *	2003-12-22	2009-03-24	Eli Lilly And Company	Triazole PPAR modulators
JP2005206492A (ja)	2004-01-21	2005-08-04	Sankyo Co Ltd	スルホンアミド化合物
KR20060114376A (ko)	2004-01-30	2006-11-06	니뽄 다바코 산교 가부시키가이샤	식욕 감퇴 화합물
EP1760071A4 (fr)	2004-06-23	2008-03-05	Ono Pharmaceutical Co	Composé ayant une activité de liaison aux récepteurs s1p et utilisation de celui-ci
TW200606137A (en) *	2004-07-02	2006-02-16	Sankyo Co	Urea derivatives
WO2006019020A1 (fr)	2004-08-16	2006-02-23	Sankyo Company, Limited	Urées de substitution
MX2007004217A (es)	2004-10-15	2007-06-11	Bayer Pharmaceuticals Corp	Preparacion y uso de derivados de acido bifenil-4-il-carbonilamino para el tratamiento de obesidad.
WO2006054370A1 (fr)	2004-11-16	2006-05-26	Use-Techno Corporation	Agents d’inhibition de la gluconeogenese
MX2007007101A (es) *	2004-12-14	2007-08-21	Astrazeneca Ab	Derivados de oxadiazol como inhibidores de acil coa:diacilglicerol aciltransferasa.
WO2006082952A1 (fr)	2005-02-01	2006-08-10	Takeda Pharmaceutical Company Limited	Composé amide
CN101115711A (zh)	2005-02-07	2008-01-30	霍夫曼-拉罗奇有限公司	二酰基甘油酰基转移酶(dgat)的抑制剂
CN101198333A (zh)	2005-04-19	2008-06-11	拜尔药品公司	芳烷基酸衍生物及其用途
CN101171231A (zh)	2005-05-10	2008-04-30	霍夫曼-拉罗奇有限公司	二酰基甘油酰基转移酶抑制剂
EP1893592A1 (fr) *	2005-06-11	2008-03-05	AstraZeneca AB	Dérivés d oxadiazole en tant qu inhibiteurs de la diacylglycérol acyltransférase (dgat)
WO2007007588A1 (fr)	2005-07-08	2007-01-18	Ono Pharmaceutical Co., Ltd.	Compose comportant un groupe cyclique ayant un noyau plan
JP2009505962A (ja)	2005-07-29	2009-02-12	バイエル・ヘルスケア・エルエルシー	肥満を治療するためのビフェニルアミノ酸誘導体の製造および使用
JP2007131584A (ja)	2005-11-11	2007-05-31	Sankyo Co Ltd	新規ベンゾオキサゾール誘導体
EP1963313B1 (fr) *	2005-11-28	2012-11-14	Madrigal Pharmaceuticals, Inc.	Inhibiteurs de diacylglycérol acyltransférase (dgat)
JP2007191471A (ja)	2005-12-21	2007-08-02	Sankyo Co Ltd	ウレア誘導体を含有する医薬
AR058562A1 (es) *	2005-12-22	2008-02-13	Astrazeneca Ab	Derivados de pirimido [4,5 b] (1,4) oxazinas , procedimientos de obtencion y su uso como inhibidores de acetil coa y dgat 1
WO2007074753A1 (fr)	2005-12-27	2007-07-05	Daiichi Sankyo Company, Limited	Produit pharmaceutique comprenant un dérivé de l'urée substitué
WO2007126957A2 (fr)	2006-03-31	2007-11-08	Novartis Ag	Nouveaux composés
CN101541747B (zh)	2006-04-21	2012-11-14	伊莱利利公司	作为11-β-羟基甾族化合物脱氢酶1的抑制剂的联苯基酰胺内酰胺衍生物
US20080064717A1 (en)	2006-05-19	2008-03-13	Rajesh Iyengar	Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
US20080015227A1 (en)	2006-05-19	2008-01-17	Kym Philip R	Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
CA2651663A1 (fr)	2006-05-30	2007-12-06	Astrazeneca Ab	Composes chimiques
BRPI0712802A2 (pt)	2006-05-30	2012-10-23	Astrazeneca Ab	composto, métodos para produzir uma inibição da atividade de dgat1, e para tratar diabete melito e/ou obesidade em um animal de sangue quente, uso de um composto, composição farmacêutica, e, processo para preparar um composto
CN101460469A (zh) *	2006-06-06	2009-06-17	阿斯利康(瑞典)有限公司	化合物
JP2009539818A (ja)	2006-06-08	2009-11-19	アストラゼネカアクチボラグ	ベンゾイミダゾールおよび糖尿病の処置のためのその使用
GB0611507D0 (en)	2006-06-10	2006-07-19	Astrazeneca Ab	Chemical compounds
GB0611506D0 (en) *	2006-06-10	2006-07-19	Astrazeneca Ab	Chemical compounds
GB0611552D0 (en)	2006-06-12	2006-07-19	Astrazeneca Ab	Chemical compounds
JP2009544616A (ja)	2006-07-21	2009-12-17	武田薬品工業株式会社	アミド化合物
US20120065196A1 (en)	2006-07-21	2012-03-15	Shuji Kitamura	Amide compounds
US7569590B2 (en) *	2006-09-19	2009-08-04	Bristol-Myers Squibb Company	Use of thianecarboxamides as dgat inhibitors
KR100811100B1 (ko)	2006-09-27	2008-03-06	한국생명공학연구원	벤즈아졸 유도체를 유효성분으로 함유하는 대사성 질환예방 및 치료용 약학적 조성물
KR100795462B1 (ko)	2006-09-27	2008-01-16	한국생명공학연구원	인돌 유도체, 이의 제조방법 및 이를 유효성분으로함유하는 대사성 질환 예방 및 치료용 약학적 조성물
BRPI0717845A2 (pt)	2006-10-04	2015-06-16	Hoffmann La Roche	Uso de compostos, composições farmacêuticas e métodos para o tratamento e/ou profilaxia de enfermidades que podem ser tratadas com agentes de elevação de colesterol-hdl e compostos
WO2008046216A1 (fr)	2006-10-18	2008-04-24	Methylgene, Inc.	Inhibiteurs de kinase et leurs utilisations
AR063311A1 (es)	2006-10-18	2009-01-21	Novartis Ag	Compuestos organicos
WO2008058402A1 (fr)	2006-11-17	2008-05-22	Queen's University At Kingston	Composés et procédés pour traiter des troubles de repliement de protéine
BRPI0719352A2 (pt)	2006-11-29	2017-10-24	Abbott Lab	inibidores de enzima diacilglicerol o-aciltransferase tipo 1
JP2010512410A (ja)	2006-12-11	2010-04-22	ノバルティスアーゲー	心筋虚血を予防または処置するための方法
US20100093733A1 (en)	2007-02-15	2010-04-15	Prosidion Limited	Amide and urea derivatives for the treatment of metabolic diseases
GB0707662D0 (en)	2007-04-20	2007-05-30	Astrazeneca Ab	Chemical compounds
CA2685529A1 (fr) *	2007-04-30	2008-11-06	Abbott Laboratories	Inhibiteurs d'enzyme diacylglycerol o-acyltransferase de type 1
US8058299B2 (en) *	2007-05-22	2011-11-15	Via Pharmaceuticals, Inc.	Diacylglycerol acyltransferase inhibitors
CN101932562B (zh) *	2007-12-20	2013-06-12	阿斯利康(瑞典)有限公司	作为dgat1抑制剂190的氨基甲酰基化合物
JP2010132590A (ja)	2008-12-03	2010-06-17	Astellas Pharma Inc	オキサジアゾール化合物
MX2011006672A (es) *	2008-12-19	2011-07-20	Astrazeneca Ab	Derivados de 1,3,4-oxadiazol y sus usos para tratar diabetes.

2007
- 2007-05-29 CA CA002651663A patent/CA2651663A1/fr not_active Abandoned
- 2007-05-29 CN CN2007800202196A patent/CN101460470B/zh not_active Expired - Fee Related
- 2007-05-29 AU AU2007266890A patent/AU2007266890B2/en not_active Ceased
- 2007-05-29 MX MX2008015226A patent/MX2008015226A/es not_active Application Discontinuation
- 2007-05-29 BR BRPI0712796-0A patent/BRPI0712796A2/pt not_active IP Right Cessation
- 2007-05-29 KR KR1020087029466A patent/KR20090010092A/ko not_active Withdrawn
- 2007-05-29 JP JP2009512663A patent/JP2009538891A/ja active Pending
- 2007-05-29 US US12/302,192 patent/US8003676B2/en not_active Expired - Fee Related
- 2007-05-29 WO PCT/GB2007/001981 patent/WO2007138304A1/fr not_active Ceased
- 2007-05-29 EP EP07732997A patent/EP2041099A1/fr not_active Withdrawn
- 2007-05-29 NZ NZ572585A patent/NZ572585A/en not_active IP Right Cessation
2008
- 2008-11-05 NO NO20084663A patent/NO20084663L/no not_active Application Discontinuation
- 2008-11-05 IL IL195125A patent/IL195125A0/en unknown
- 2008-11-13 ZA ZA200809689A patent/ZA200809689B/xx unknown

Also Published As

Publication number	Publication date
JP2009538891A (ja)	2009-11-12
AU2007266890A1 (en)	2007-12-06
CN101460470B (zh)	2011-05-18
AU2007266890B2 (en)	2011-02-17
MX2008015226A (es)	2008-12-12
CN101460470A (zh)	2009-06-17
EP2041099A1 (fr)	2009-04-01
BRPI0712796A2 (pt)	2012-10-02
KR20090010092A (ko)	2009-01-28
WO2007138304A1 (fr)	2007-12-06
IL195125A0 (en)	2011-08-01
ZA200809689B (en)	2010-04-28
US20100029727A1 (en)	2010-02-04
CA2651663A1 (fr)	2007-12-06
NZ572585A (en)	2011-02-25
US8003676B2 (en)	2011-08-23

Legal Events

Date	Code	Title	Description
2012-12-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO20084663L (no)	2008-12-12	1,3,4-oksadiazol-derivater som DGAT1 inhibitorer
NO20084732L (no)	2008-12-12	Substituerte 5-fenylamino- 1, 3, 4-oksadiazol-2-ylcarbonylamino-4-fenoksy-cycloheksane karboksylsyre som inhibitorer av acetyl koenzym A diacylglyserol acyltransferase
NO20091858L (no)	2009-07-08	Hydrobenzamid derivater som inhibitorer av HSP90
NO20083434L (no)	2008-08-12	Benzamid- og heteroarenderivater
NO20091893L (no)	2009-07-09	Nye 1,4-benzotiepin-1,1-dioksidderivater som er substituert med benzylgrupper, fremgangsmater for fremstilling av medisiner inneholdende forbindelsene og anvendelse derav.
ZA200810739B (en)	2010-03-31	Pesticide containing novel pyridyl-methanamine derivative or its salt
NO20092033L (no)	2009-08-06	Nye forbindelser
EA201001013A1 (ru)	2010-12-30	Бис(сульфониламино)производные для применения в терапии
NO20080865L (no)	2008-04-18	Spirokromanonderivater som acetyl-koenzym-A-karboksylase(ACC)inhibitorer
TNSN08407A1 (en)	2010-04-14	Organic compounds
WO2007122634A3 (fr)	2007-12-21	Inhibiteurs de kinase
EA201000805A1 (ru)	2010-12-30	Бис-(сульфониламино)производные в терапии 066
NO20080789L (no)	2008-02-13	1,4-benzotiazepin 1,1-dioksidderivater, fremgangsmate for fremstilling derav, medikamenter inneholdende denne forbindelsen og anvendelse derav som et hypolipid
NO20064297L (no)	2006-11-23	Aminoalkoholforbindelse
Bua et al.	2019	Click-tailed benzenesulfonamides as potent bacterial carbonic anhydrase inhibitors for targeting Mycobacterium tuberculosis and Vibrio cholerae
MX2010001848A (es)	2010-03-10	Derivados de oxadiazol como inhibidores de diacilglicerolaciltrans ferasa (dgat).
NO20052074L (no)	2005-06-01	Substituerte benzoksazinoner og anvendelser derav.
NO20065880L (no)	2006-12-20	3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor
NO20081216L (no)	2008-05-13	Amidderivater
NO20072310L (no)	2007-06-14	1,2,4-triazolylaminoaryl (heteroaryl) sulfonamidderivater
ATE529424T1 (de)	2011-11-15	1-ää2-amino-3-(substituiertes alkyl)-3h- benzimidazolylümethylü-3-substituierte-1,3- dihydrobenzimidazol-2-one als replikationshemmer des respiratorischen syncytialvirus
DK1634595T3 (da)	2008-11-24	N-Phenylbenzamidderivater som medikamenter til behandling af kronisk obstruktiv lungesygdom (KOL)
NO20074631L (no)	2007-11-20	Nye 3-aryl-1,2-benzisoksazolderivater, forbindelser inneholdende de samme og deres anvendelse
NO20055167L (no)	2006-05-04	Nye benzotiadiazinforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem
NO20041761L (no)	2004-04-29	Nye hydroksyalkylindolokarbazolforbindelser, fremgangsmate for deres fremstilling og farmasoytiske sammensetninger inneholdende dem